Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 30
- Registration Number
- NCT06466122
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Kerry Rogers
- Registration Number
- NCT03943342
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 87
- Registration Number
- NCT02427451
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
© Copyright 2024. All Rights Reserved by MedPath